Low-coverage exome sequencing screen in formalin-fixed paraffin-embedded tumors reveals evidence of exposure to carcinogenic aristolochic acid

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 12, 2015, Pages 1873-1881

  Castells, Xavier ^a   Karanović, Sandra ^b   Ardin, Maude ^a   Tomić, Karla ^c   Xylinas, Evanguelos ^d   Durand, Geoffroy ^a   Villar, Stephanie ^a   Forey, Nathalie ^a   Le Calvez Kelm, Florence ^a   Voegele, Catherine ^a   Karlović, Krešimir ^c   Mišić, Maja ^c   Dittrich, Damir ^c   Dolgalev, Igor ^e   McKay, James ^a   Shariat, Shahrokh F ^d   Sidorenko, Viktoria S ^f   Fernandes, Andrea ^f   Heguy, Adriana ^e   Dickman, Kathleen G ^f   Olivier, Magali ^a   Grollman, Arthur P ^f   Jelaković, Bojan ^b   Zavadil, Jiri ^a   more..

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KBC Zagreb   (Croatia)

^c DR JOSIP BEN EVI GENERAL HOSPITAL   (Croatia)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC ENZYME; ARISTOLOCHIC ACID; ENZYME; FORMALDEHYDE; PARAFFIN; UNCLASSIFIED DRUG; ARISTOLOCHIC ACID I; CARCINOGEN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EXOME; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; PRIORITY JOURNAL; UROGENITAL TRACT TUMOR; WHOLE EXOME SEQUENCING; CHEMISTRY; DNA SEQUENCE; DRUG EFFECTS; GENETICS; NEOPLASM; PATHOLOGY; PROCEDURES; TISSUE FIXATION;

ARISTOLOCHIC ACIDS; CARCINOGENS; EXOME; FORMALDEHYDE; HUMANS; NEOPLASMS; PARAFFIN EMBEDDING; SEQUENCE ANALYSIS, DNA; TISSUE FIXATION;

EID: 84948732266     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0553     Document Type: Article

References (42)

1. IARC monographs on the evaluation of carcinogenic risks to humans volume 100A; A review of human carcinogens: pharmaceuticals. Lyon: International Agency for Research on Cancer; 2012.
2. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008;74:158-69.
3. Grollman AP. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013;54:1-7.
4. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A 2007;104:12129-34.
5. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686-92.
6. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012;44: 1117-21.
7. Poon SL, McPherson JR, Tan P, Teh BT, Rozen SG. Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. Genome Med 2014;6:24.
8. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, et al. Genomewide mutational signatures of aristolochic acid and its application as a screening tool. Sci Translat Med 2013;5:197ra01.
9. Jelakovic B, Castells X, Tomic K, Ardin M, Karanovic S, Zavadil J. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int J Cancer 2015;136: 2967-72.
10. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzalez-Porta M, Wozniak MB, et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun 2014;5:5135.
11. Poon S, Huang M, Choo Y, McPherson J, Yu W, Heng H, et al. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med 2015;7:38.
12. Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun 2014;5:5696.
13. Jelakovic B, Karanovic S, Vukovic-Lela I, Miller F, Edwards KL, Nikolic J, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012;81:559-67.
14. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996;56: 2025-8.
15. Schmeiser HH, Nortier JL, Singh R, da Costa GG, Sennesael J, Cassuto-Viguier E, et al. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer 2014;135:502-7.
16. Yun BH, Yao L, Jelakovic B, Nikolic J, Dickman KG, Grollman AP, et al. Formalin-fixed paraffin-embedded tissue as a source for quantitation of carcinogen DNA adducts: aristolochic acid as a prototype carcinogen. Carcinogenesis 2014;35:2055-61.
17. Dong H, Suzuki N, Torres MC, Bonala RR, Johnson F, Grollman AP, et al. Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos 2006;34:1122-7.
18. Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, et al. Biomonitoring of aristolactam-DNA adducts in human tissues using ultraperformance liquid chromatography/ion-trap mass spectrometry. Chem Res Toxicol 2012;25:1119-31.
19. Yun BH, Rosenquist TA, Nikolic J, Dragicevic D, Tomic K, Jelakovic B, et al. Human formalin-fixed paraffin-embedded tissues: an untapped specimen for biomonitoring of carcinogen DNA adducts bymass spectrometry. Anal Chem 2013;85:4251-8.
20. Hollstein M, Moriya M, Grollman AP, Olivier M. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat Res 2013;753:41-9.
21. Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, et al. Mutational signature of aristolochic acid exposure as revealed by wholeexome sequencing. Sci Translat Med 2013;5:197ra02.
22. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-21.
23. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015;43:D805-11.
24. Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, et al. Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat Med J 2005;46:116-25.
25. Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B, et al. TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer 2011;129:1532-6.
26. Jelakovic B, Nikolic J, Radovanovic Z, Nortier J, Cosyns JP, Grollman AP, et al. Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. Nephrol Dial Transplant 2014;29:2020-7.
27. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-5.
28. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
29. Bailey JA, Gu Z, Clark RA, Reinert K, Samonte RV, Schwartz S, et al. Recent segmental duplications in the human genome. Science 2002; 297:1003-7.
30. Lee DD, Seung HS. Learning the parts of objects by non-negative matrix factorization. Nature 1999;401:788-91.
31. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 2010;11:367.
32. Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallee MP, et al. Modelling mutational landscapes of human cancers in vitro. Sci Rep 2014;4:4482.
33. Huang daW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
35. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501.
36. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 2013;14:765-80.
37. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013;153:38-55.
38. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 2013;3:2650.
39. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
40. Clyne M. Bladder cancer: aristolochic acid-one of the most potent carcinogens known to man. Nat Rev Urol 2013;10:552.
41. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Reports 2013;3:246-59.
42. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet 2014;15:585-98.